Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon

Inclusion Criteria:

• Adult subjects, 22 years or older with moderate to severe convexity or fullnessassociated with periorbital fat.

• Subject has moderate to severe eyebags per Goldberg and Simon's Orbital Fat GradingSystem, per protocol requirements.

• Willing and able to attend all study visits.

Exclusion Criteria:

• Any signs or symptoms of periorbital disease in the study eye and relatedcomplications, as determined by the investigator.

• Active thyroid eye disease, chronic ocular inflammatory orbital disease or otherophthalmic disease that could confound study results.

• Evidence of infection, or clinically significant periocular, periorbital orconjunctival inflammation or conditions that in the opinion of the investigatorwould constitute a risk or could confound the study results.

• History of hypersensitivity to prostaglandin analogs or prostaglandin PF2alphatreatments.

• Known hypersensitivity to any component of the investigational product formulation.

• Use of periocular corticosteroids within 2 months prior to Screening.

• Use of intravitreal (IVT) injections within 3 weeks prior to Screening in the studyeye.

• Surgical or laser treatment of the eye or surrounding anatomical structures within 6months prior to Screening in the study eye.

• Previous history of lower incisional eyelid surgery.

• Previous history of undereye lid tattoo or underage lash extensions.

• Previous history of infra-orbital or anterior medical cheek fillers within 24 monthsprior to Screening.

• The subject has received botulinum toxin treatment of the inferior pretarsalorbicularis oculi muscle within 6 months of the first injection.

• History of ocular trauma in the study eye within 6 months prior to Screening.

• Any concurrent disease that would require medical or surgical intervention duringthe study in the study eye (e.g., retinal detachment, significant cataract,uncontrolled glaucoma).

• Facial nerve injury or abnormal weakness, other facial rejuvenation injections (notincluding botulinum toxin) in the treated area, facial surgery, or facial traumawithin 3 months prior to Screening. History or concurrent systemic condition thatwould preclude the safe administration of the study treatment or confound theresults of the safety (e.g., renal or hepatic impairment).

• Any laboratory findings that based on clinical assessment of the investigator wouldplace the subject at risk or could confound th study results.

• Significant infraorbital vascular prominence.

• Women of childbearing potential who are pregnant, nursing, planning a pregnancy, ornot using a medically acceptable form of birth control.

• Participation in an interventional clinical study within 30 days prior to Screening.

• Any other criterion that based on the clinical judgement of the investigator mayplace the subject at risk or confound study results.